0001041024false12-312022Q30.090.0900010410242022-01-012022-09-3000010410242022-11-11xbrli:shares00010410242022-09-30iso4217:USD00010410242021-12-31iso4217:USDxbrli:shares00010410242022-07-012022-09-3000010410242021-07-012021-09-3000010410242021-01-012021-09-300001041024us-gaap:PreferredStockMember2021-12-310001041024us-gaap:CommonStockMember2021-12-310001041024us-gaap:AdditionalPaidInCapitalMember2021-12-310001041024us-gaap:RetainedEarningsMember2021-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001041024us-gaap:RetainedEarningsMember2022-01-012022-03-3100010410242022-01-012022-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001041024us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001041024us-gaap:PreferredStockMember2022-03-310001041024us-gaap:CommonStockMember2022-03-310001041024us-gaap:AdditionalPaidInCapitalMember2022-03-310001041024us-gaap:RetainedEarningsMember2022-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100010410242022-03-310001041024us-gaap:RetainedEarningsMember2022-04-012022-06-3000010410242022-04-012022-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001041024rmti:PublicOfferingMemberus-gaap:CommonStockMember2022-04-012022-06-300001041024rmti:PublicOfferingMemberus-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001041024rmti:PublicOfferingMember2022-04-012022-06-300001041024us-gaap:CommonStockMemberrmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024us-gaap:AdditionalPaidInCapitalMemberrmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024rmti:AtTheMarketOfferingMember2022-04-012022-06-300001041024us-gaap:PreferredStockMember2022-04-012022-06-300001041024us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001041024us-gaap:CommonStockMember2022-04-012022-06-300001041024us-gaap:PreferredStockMember2022-06-300001041024us-gaap:CommonStockMember2022-06-300001041024us-gaap:AdditionalPaidInCapitalMember2022-06-300001041024us-gaap:RetainedEarningsMember2022-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000010410242022-06-300001041024us-gaap:RetainedEarningsMember2022-07-012022-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001041024us-gaap:CommonStockMember2022-07-012022-09-300001041024us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001041024us-gaap:PreferredStockMember2022-09-300001041024us-gaap:CommonStockMember2022-09-300001041024us-gaap:AdditionalPaidInCapitalMember2022-09-300001041024us-gaap:RetainedEarningsMember2022-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001041024us-gaap:CommonStockMember2020-12-310001041024us-gaap:AdditionalPaidInCapitalMember2020-12-310001041024us-gaap:RetainedEarningsMember2020-12-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100010410242020-12-310001041024us-gaap:RetainedEarningsMember2021-01-012021-03-3100010410242021-01-012021-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001041024us-gaap:CommonStockMember2021-01-012021-03-310001041024us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001041024us-gaap:CommonStockMember2021-03-310001041024us-gaap:AdditionalPaidInCapitalMember2021-03-310001041024us-gaap:RetainedEarningsMember2021-03-310001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100010410242021-03-310001041024us-gaap:RetainedEarningsMember2021-04-012021-06-3000010410242021-04-012021-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001041024us-gaap:CommonStockMember2021-04-012021-06-300001041024us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001041024us-gaap:CommonStockMember2021-06-300001041024us-gaap:AdditionalPaidInCapitalMember2021-06-300001041024us-gaap:RetainedEarningsMember2021-06-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000010410242021-06-300001041024us-gaap:RetainedEarningsMember2021-07-012021-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001041024us-gaap:CommonStockMemberrmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024us-gaap:AdditionalPaidInCapitalMemberrmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024rmti:AtTheMarketOfferingMember2021-07-012021-09-300001041024us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001041024us-gaap:CommonStockMember2021-09-300001041024us-gaap:AdditionalPaidInCapitalMember2021-09-300001041024us-gaap:RetainedEarningsMember2021-09-300001041024us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000010410242021-09-30rmti:facilityutr:sqft0001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheOneMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-04-062022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheOneMember2022-04-062022-04-060001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:ShareIssuanceTrancheTwoMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-152022-06-150001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheTwoMember2022-06-152022-06-150001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-152022-06-150001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-04-080001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-09-300001041024rmti:RegisteredDirectOfferingMember2022-05-302022-05-300001041024rmti:RegisteredDirectOfferingMember2022-05-300001041024rmti:RegisteredDirectOfferingWarrantsMember2022-05-300001041024rmti:RegisteredDirectOfferingWarrantsMemberrmti:RegisteredDirectOfferingMember2022-05-300001041024rmti:PIPEPurchaseAgreementWarrantMember2022-05-300001041024rmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-05-3000010410242022-05-302022-06-020001041024us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001041024us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001041024us-gaap:RestrictedStockMember2022-01-012022-09-300001041024us-gaap:RestrictedStockMember2021-01-012021-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001041024us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001041024us-gaap:ConvertiblePreferredStockMember2022-01-012022-09-300001041024us-gaap:ConvertiblePreferredStockMember2021-01-012021-09-300001041024us-gaap:WarrantMember2022-01-012022-09-300001041024us-gaap:WarrantMember2021-01-012021-09-3000010410242022-05-092022-05-09xbrli:purermti:agreement0001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2022-01-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-07-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2022-01-012022-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2022-01-012022-09-300001041024rmti:DrugRevenueMember2022-07-012022-09-300001041024country:USrmti:DrugRevenueMember2022-07-012022-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:DrugRevenueMember2022-01-012022-09-300001041024country:USrmti:DrugRevenueMember2022-01-012022-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-07-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2022-07-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-01-012022-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-07-012022-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-07-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2022-07-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-01-012022-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2022-01-012022-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2022-01-012022-09-300001041024rmti:ConcentrateProductsMember2022-07-012022-09-300001041024country:USrmti:ConcentrateProductsMember2022-07-012022-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2022-07-012022-09-300001041024rmti:ConcentrateProductsMember2022-01-012022-09-300001041024country:USrmti:ConcentrateProductsMember2022-01-012022-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2022-01-012022-09-300001041024country:US2022-07-012022-09-300001041024us-gaap:NonUsMember2022-07-012022-09-300001041024country:US2022-01-012022-09-300001041024us-gaap:NonUsMember2022-01-012022-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberus-gaap:NonUsMemberrmti:DrugProductSalesMember2021-01-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001041024country:USrmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001041024rmti:DrugLicenseFeeMemberus-gaap:TransferredOverTimeMemberus-gaap:NonUsMember2021-01-012021-09-300001041024rmti:DrugRevenueMember2021-07-012021-09-300001041024country:USrmti:DrugRevenueMember2021-07-012021-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:DrugRevenueMember2021-01-012021-09-300001041024country:USrmti:DrugRevenueMember2021-01-012021-09-300001041024rmti:DrugRevenueMemberus-gaap:NonUsMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-07-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2021-07-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-01-012021-09-300001041024country:USus-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMember2021-01-012021-09-300001041024us-gaap:TransferredAtPointInTimeMemberrmti:ConcentrateProductSalesMemberus-gaap:NonUsMember2021-01-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-07-012021-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-07-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2021-07-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-01-012021-09-300001041024country:USus-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMember2021-01-012021-09-300001041024us-gaap:TransferredOverTimeMemberrmti:ConcentrateProductLicenseFeeMemberus-gaap:NonUsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMember2021-07-012021-09-300001041024country:USrmti:ConcentrateProductsMember2021-07-012021-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2021-07-012021-09-300001041024rmti:ConcentrateProductsMember2021-01-012021-09-300001041024country:USrmti:ConcentrateProductsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMemberus-gaap:NonUsMember2021-01-012021-09-300001041024country:US2021-07-012021-09-300001041024us-gaap:NonUsMember2021-07-012021-09-300001041024country:US2021-01-012021-09-300001041024us-gaap:NonUsMember2021-01-012021-09-300001041024rmti:ConcentrateProductsMember2021-12-310001041024rmti:ConcentrateProductsMember2022-09-300001041024rmti:BaxterHealthcareOrganizationMember2022-09-300001041024rmti:TrifericInventoryMember2022-09-300001041024rmti:TrifericAPIMember2022-09-300001041024rmti:TrifericInventoryMember2022-01-012022-09-300001041024us-gaap:LeaseholdImprovementsMember2022-09-300001041024us-gaap:LeaseholdImprovementsMember2021-12-310001041024us-gaap:MachineryAndEquipmentMember2022-09-300001041024us-gaap:MachineryAndEquipmentMember2021-12-310001041024us-gaap:OfficeEquipmentMember2022-09-300001041024us-gaap:OfficeEquipmentMember2021-12-310001041024us-gaap:OtherMachineryAndEquipmentMember2022-09-300001041024us-gaap:OtherMachineryAndEquipmentMember2021-12-310001041024rmti:BaxterHealthcareOrganizationMember2014-10-012014-10-310001041024rmti:BaxterHealthcareOrganizationMember2022-07-012022-09-300001041024rmti:BaxterHealthcareOrganizationMember2022-01-012022-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-07-012021-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-01-012021-09-300001041024rmti:BaxterHealthcareOrganizationMember2021-12-310001041024rmti:WanbangBiopharmaceuticalMember2016-01-012016-12-310001041024rmti:WanbangBiopharmaceuticalMember2021-07-012021-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-07-012022-09-300001041024rmti:WanbangBiopharmaceuticalMember2021-01-012021-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-01-012022-09-300001041024rmti:WanbangBiopharmaceuticalMember2022-09-300001041024rmti:WanbangBiopharmaceuticalMember2021-12-310001041024rmti:SunPharmaAgreementsMember2020-01-012020-01-310001041024rmti:SunPharmaAgreementsMember2021-07-012021-09-300001041024rmti:SunPharmaAgreementsMember2022-07-012022-09-300001041024rmti:SunPharmaAgreementsMember2022-01-012022-09-300001041024rmti:SunPharmaAgreementsMember2021-01-012021-09-300001041024rmti:SunPharmaAgreementsMember2022-09-300001041024rmti:SunPharmaAgreementsMember2021-12-310001041024rmti:JeilPharmaAgreementsMember2020-09-012020-09-300001041024rmti:JeilPharmaAgreementsMember2022-05-012022-05-310001041024rmti:JeilPharmaAgreementsMember2022-07-012022-09-300001041024rmti:JeilPharmaAgreementsMember2022-01-012022-09-300001041024rmti:JeilPharmaAgreementsMember2021-07-012021-09-300001041024rmti:JeilPharmaAgreementsMember2021-01-012021-09-300001041024rmti:JeilPharmaAgreementsMember2022-09-300001041024rmti:JeilPharmaAgreementsMember2021-12-310001041024rmti:DrogsanAgreementsMember2021-06-012021-06-300001041024rmti:DrogsanAgreementsMember2021-07-012021-09-300001041024rmti:DrogsanAgreementsMember2022-07-012022-09-300001041024rmti:DrogsanAgreementsMember2022-01-012022-09-300001041024rmti:DrogsanAgreementsMember2021-01-012021-09-300001041024rmti:DrogsanAgreementsMember2022-09-300001041024rmti:DrogsanAgreementsMember2021-12-310001041024rmti:DaVitaHealthcarePartnersIncMemberus-gaap:PrivatePlacementMemberrmti:ShareIssuanceTrancheTwoMemberrmti:SeriesXConvertiblePreferredStockMember2022-06-162022-06-160001041024rmti:DaVitaHealthcarePartnersIncMemberrmti:ShareIssuanceTrancheTwoMember2022-06-162022-06-160001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-062022-04-060001041024rmti:SeriesXConvertiblePreferredStockMember2022-04-060001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-06-302022-06-300001041024rmti:CantorFitzgeraldCoMemberrmti:ControlledEquityOfferingMember2022-06-300001041024rmti:RegisteredDirectOfferingWarrantsMember2022-09-300001041024rmti:PIPEPurchaseAgreementWarrantMember2022-09-300001041024rmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-07-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-07-012021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-01-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-01-012021-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2022-07-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-07-012021-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-01-012021-09-300001041024rmti:ServiceBasedAwardsMember2022-07-012022-09-300001041024rmti:ServiceBasedAwardsMember2021-07-012021-09-300001041024rmti:ServiceBasedAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedStockOptionAwardsMember2021-01-012021-09-300001041024rmti:PerformanceBasedAwardsMember2022-07-012022-09-300001041024rmti:PerformanceBasedAwardsMember2021-07-012021-09-300001041024rmti:PerformanceBasedAwardsMember2022-01-012022-09-300001041024rmti:PerformanceBasedAwardsMember2021-01-012021-09-300001041024us-gaap:RestrictedStockMember2022-01-012022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-12-310001041024rmti:PerformanceBasedRestrictedStockAwardsMember2022-09-300001041024rmti:PerformanceBasedRestrictedStockAwardsMember2020-12-310001041024rmti:PerformanceBasedRestrictedStockAwardsMember2021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-12-310001041024rmti:ServiceBasedRestrictedStockUnitsMember2022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMember2020-12-310001041024rmti:ServiceBasedRestrictedStockUnitsMember2021-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MinimumMember2022-01-012022-09-300001041024rmti:ServiceBasedRestrictedStockUnitsMembersrt:MaximumMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2022-09-300001041024srt:MaximumMemberrmti:ServiceBasedStockOptionAwardsMember2022-09-300001041024rmti:ServiceBasedStockOptionAwardsMembersrt:MinimumMember2022-01-012022-09-300001041024srt:MaximumMemberrmti:ServiceBasedStockOptionAwardsMember2022-01-012022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2021-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2021-01-012021-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2022-09-300001041024rmti:ServiceBasedStockOptionAwardsMember2020-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2020-01-012020-12-310001041024rmti:ServiceBasedStockOptionAwardsMember2021-09-3000010410242018-10-072018-10-070001041024rmti:MasterServicesAndIpAgreementMember2022-09-300001041024srt:MaximumMember2022-09-300001041024stpr:MIrmti:WixomMichiganPropertyOneMember2022-09-300001041024rmti:WixomMichiganPropertyTwoMemberstpr:MI2022-09-300001041024stpr:TX2022-09-300001041024stpr:SC2022-09-300001041024stpr:NJ2022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheOneMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheTwoMember2020-03-160001041024rmti:TermLoanTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-160001041024us-gaap:MediumTermNotesMemberrmti:TermLoanTrancheOneMember2020-03-162020-03-160001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024srt:MaximumMemberrmti:TermLoanTrancheTwoAndTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-160001041024rmti:TermLoanTrancheTwoAndTrancheThreeMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024rmti:TermLoanMembersrt:MinimumMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024srt:MaximumMemberrmti:TermLoanMemberus-gaap:MediumTermNotesMember2020-03-162020-03-160001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-07-012022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-07-012021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-01-012022-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-01-012021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-09-300001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2021-09-012021-09-30rmti:installment0001041024rmti:TermLoanMemberus-gaap:MediumTermNotesMember2022-09-300001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-06-020001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-06-022022-06-020001041024us-gaap:NotesPayableToBanksMemberrmti:A540NotePayableMember2022-09-300001041024us-gaap:SubsequentEventMemberrmti:PIPEPurchaseAgreementPreFundedWarrantMember2022-10-280001041024us-gaap:SubsequentEventMember2022-10-282022-10-280001041024rmti:TermLoanMemberus-gaap:SubsequentEventMemberus-gaap:MediumTermNotesMember2022-11-10

United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
__________________________________________________
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                              to                              
Commission File Number: 000-23661
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware38-3317208
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
30142 S. Wixom Road, Wixom, Michigan
48393
(Address of principal executive offices)(Zip Code)
(248) 960-9009
(Registrant’s telephone number, including area code)


(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes    ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒  Yes    ☐  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes  ☒
  No
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading SymbolName of each exchange on which registered:
Common Stock, par value $0.0001RMTI
Nasdaq Capital Market
The number of shares of common stock outstanding as of November 11, 2022 was 11,632,673.


Rockwell Medical, Inc. and Subsidiaries
Index to Form 10-Q
Page
2

PART I – FINANCIAL INFORMATION
Item 1.  Financial Statements
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars In Thousands)
September 30,
2022		December 31,
2021
(Unaudited)
ASSETS
Cash and Cash Equivalents$12,980 $13,280 
Investments Available-for-Sale14,584 9,158 
Accounts Receivable, net7,367 5,913 
Inventory, net5,020 4,076 
Prepaid and Other Current Assets2,407 2,861 
Total Current Assets42,358 35,288 
Property and Equipment, net2,264 2,486 
Inventory, Non-Current1,193 1,523 
Right of Use Assets, net6,928 7,737 
Goodwill921 921 
Other Non-Current Assets522 619 
Total Assets$54,186 $48,574 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable$3,051 $3,739 
Accrued Liabilities5,887 5,090 
Lease Liability - Current1,992 2,004 
Deferred License Revenue - Current2,164 2,171 
Term Loan - Net of Issuance Costs5,131 7,381 
Insurance Financing Note Payable1,006 437 
Customer Deposits107 144 
Total Current Liabilities19,338 20,966 
Lease Liability - Long-Term5,171 5,887 
Term Loan, Net of Issuance Costs8,962 13,186 
Deferred License Revenue - Long-Term4,565 5,986 
Long Term Liability - Other14 14 
Total Liabilities38,050 46,039 
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 15,000 and nil shares issued and outstanding at September 30, 2022 and December 31, 2021
— — 
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 11,152,673 and 8,544,225 shares issued and outstanding at September 30, 2022 and December 31, 2021
1 1 
Additional Paid-in Capital402,480 372,562 
Accumulated Deficit(386,399)(370,080)
Accumulated Other Comprehensive Income54 52 
Total Stockholders’ Equity16,136 2,535 
Total Liabilities and Stockholders’ Equity$54,186 $48,574 
The accompanying notes are an integral part of the condensed consolidated financial statements.
3

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Shares and Per Share Amounts)
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Net Sales$18,691 $15,988 $53,497 $46,599 
Cost of Sales17,914 16,317 51,760 46,788 
Gross Profit (Loss)777 (329)1,737 (189)
Research and Product Development469 1,221 2,963 5,445 
Selling and Marketing762 1,541 1,743 4,860 
General and Administrative3,254 3,881 11,845 11,483 
Operating Loss(3,708)(6,972)(14,814)(21,977)
Other (Expense) Income
Realized Gain on Investments— — 4 (1)
Interest Expense(476)(609)(1,497)(1,772)
Interest Income(6)— (10)17 
Total Other Expense(482)(609)(1,503)(1,756)
Net Loss$(4,190)$(7,581)$(16,317)$(23,733)
Basic and Diluted Net Loss per Share$(0.40)$(0.89)$(1.75)$(2.79)
Basic and Diluted Weighted Average Shares Outstanding10,528,148 8,534,740 9,299,788 8,520,603 
The accompanying notes are an integral part of the condensed consolidated financial statements.
4

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In Thousands)
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Net Loss$(4,190)$(7,581)$(16,317)$(23,733)
Unrealized Gain (Loss) on Available-for-Sale Debt Instrument Investments5 4 5 (4)
Foreign Currency Translation Adjustments— — (3)3 
Comprehensive Loss$(4,185)$(7,577)$(16,315)$(23,734)
The accompanying notes are an integral part of the condensed consolidated financial statements.
5

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in Thousands)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT		ACCUMULATED
OTHER
COMPREHENSIVE
INCOME		TOTAL
STOCKHOLDERS'
 (DEFICIT)
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2022— $— 8,544,225 $1 $372,562 $(370,080)$52 $2,535 
Net Loss— — — — — (7,162)— (7,162)
Foreign Currency Translation Adjustments— — — — — — (1)(1)
Stock-based Compensation— — — — (179)— — (179)
Balance as of March 31, 2022— $— 8,544,225 $1 $372,383 $(377,242)$51 $(4,807)
Net Loss— — — — — (4,967)— (4,967)
Foreign Currency Translation Adjustments— — — — — — (2)(2)
Issuance of common stock, net of offering costs/Public Offering— — 844,613 — 14,893 — — 14,893 
Issuance of common stock, net of offering costs/At-the-Market Offering— — 7,500 — 15 — — 15 
Issuance of preferred stock, net of offering costs15,000 — — — 14,916 — — 14,916 
Vesting of Restricted Stock Units Issued, net of taxes withheld— — 10,958 — — — — — 
Stock-based Compensation and modification expense— — — — 97 — — 97 
Balance as of June 30, 202215,000 $— 9,407,296 $1 $402,304 $(382,209)$49 $20,145 
Net Loss— — — — — (4,190)— (4,190)
Unrealized Gain on Available-for-Sale Investments— — — — — — 5 5 
Issuance of common stock, net of offering costs/Public Offering— 1,745,377 — — — — — 
Stock-based Compensation expense— — — — 176 — — 176 
Balance as of September 30, 202215,000 $— 11,152,673 $1 $402,480 $(386,399)$54 $16,136 

    The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in Thousands)
PREFERRED STOCKCOMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT		ACCUMULATED
OTHER
COMPREHENSIVE
INCOME		TOTAL
STOCKHOLDERS'
EQUITY
SHARESAMOUNTSHARESAMOUNT
Balance as of January 1, 2021— $— 8,506,651 $1 $371,518 $(337,406)$57 $34,170 
Net Loss— — — — — (7,752)— (7,752)
Unrealized Loss on Available-for-Sale Investments— — — — — — (7)(7)
Foreign Currency Translation Adjustments— — — — — — 3 3 
Stock-based Compensation— — 2,396 — (236)— — (236)
Balance as of March 31, 2021— $— 8,509,047 $1 $371,282 $(345,158)$53 $26,178 
Net Loss— — — — — (8,400)— (8,400)
Unrealized Loss on Available-for-Sale Investments— — — — — — (1)(1)
Vesting of Restricted Stock Units Issued, net of taxes withheld— — 19,260 — (7)— — (7)
Stock-based Compensation— — — — 433 — — 433 
Balance as of June 30, 2021— $— 8,528,307 $1 $371,708 $(353,558)$52 $18,203 
Net Loss— — — — — (7,581)— (7,581)
Unrealized Gain on Available-for-Sale Investments— — — — — — 4 4 
Issued shares for services— — 14,090 — 107 — — 107 
Stock-based Compensation— — — — 361 — — 361 
Balance as of September 30, 2021— $— 8,542,397 $1 $372,176 $(361,139)$56 $11,094 
The accompanying notes are an integral part of the condensed consolidated financial statements.

6

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Thousands)
For the nine months ended September 30, 2022 and 2021
Nine Months Ended
September 30, 2022		Nine Months Ended
September 30, 2021
Cash Flows From Operating Activities:
Net Loss$(16,317)$(23,733)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization422 535 
Stock-based Compensation95 558 
Increase in Inventory Reserves307 89 
Amortization of Right of Use Asset1,518 1,312 
Amortization of Debt Financing Costs and Accretion of Debt Discount276 276 
(Gain) Loss on Disposal of Assets(3)7 
Realized (Gain) Loss on Sale of Investments Available-for-Sale(4)1 
Foreign Currency Translation Adjustment(3)3 
Changes in Assets and Liabilities:
Increase in Accounts Receivable, net(1,454)(1,865)
Increase in Inventory(921)(554)
Decrease in Prepaid and Other Assets2,058 1,760 
(Decrease) Increase in Accounts Payable(688)679 
Decrease in Lease Liability(1,435)(1,266)
Increase (Decrease) in Other Liabilities756 (825)
Decrease in Deferred License Revenue(1,427)(1,485)
Changes in Assets and Liabilities(3,111)(3,556)
Cash Used In Operating Activities(16,820)(24,508)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale(17,389)(19,107)
Sale of Investments Available-for-Sale11,972 19,286 
Purchase of Equipment(197)(408)
Cash Used In Investing Activities(5,614)(229)
Cash Flows From Financing Activities:
Payments on Debt(6,750)— 
Payments on Short Term Note Payable(941)(656)
Proceeds from the Issuance of Common Stock15,016 — 
Offering Costs from the Issuance of Common Stock(106)— 
Proceeds from the Issuance of Preferred Stock15,000 — 
Offering Costs from the Issuance of Preferred Stock(85)— 
Proceeds from the Issuance of Common Stock for payment related to services provided— 107 
Repurchase of Common Stock to Pay Employee Withholding Taxes— (6)
Cash Provided by (Used In) Financing Activities22,134 (555)
Decrease in Cash and Cash Equivalents(300)(25,292)
Cash and Cash Equivalents at Beginning of Period13,280 48,682 
Cash and Cash Equivalents at End of Period$12,980 $23,390 
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest$1,261 $1,318 
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale$5 $(4)
The accompanying notes are an integral part of the condensed consolidated financial statements.

7

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1.  Description of Business
Rockwell Medical, Inc. (“Rockwell Medical,” “Rockwell,” or the “Company”) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell has a proprietary parenteral iron product, TRIFERIC® (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC® outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC® in their respective regions.
Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure.
Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC® and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.
8

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
2.  Liquidity and Capital Resources
As of September 30, 2022, Rockwell had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million. Based on the currently available working capital and capital raises described below, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
On April 6, 2022, the Company and DaVita, Inc. ("DaVita") entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. Certain costs are subject to a cap. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or the Company will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.
On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15 million in capital within a certain timeline, which took place on June 2, 2022.
On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the three months ended September 30, 2022, the Company did not make any sales pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility.
On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.
Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.
Currently, because the Company's public float is less than $75 million, it is subject to the baby shelf limitations under its current registration statement on Form S-3, which limit the amount the Company may offer under the Form S-3. This could limit its ability to raise capital under this registration statement.

In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 for further detail).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected the Company's business and operations, including, but not limited to, its sales and marketing efforts and its research and development activities, its plant and transportation operations and the operations of third parties upon whom the Company relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.
9

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
3.  Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at September 30, 2022, condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022 and 2021, condensed consolidated statement of changes in stockholders' equity for the three and nine months ended September 30, 2022 and 2021, and condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited, but include all adjustments, consisting of normal recurring adjustments, the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at December 31, 2021 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 8, 2022. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split for the three and nine month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases
The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share
ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested restricted stock units and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented.
The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares):
As of September 30,
20222021
Options to purchase common stock1,311,691 533,784 
Unvested restricted stock awards891 7,118 
Unvested restricted stock units125,000 31,116 
Preferred stock conversion to common stock1,363,636 — 
Warrants to purchase common stock17,507,268 2,402,442 
Total20,308,486 2,974,460 
Adoption of Recent Accounting Pronouncements
The Company continually assesses new accounting pronouncements to determine their applicability. When it is determined a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures there are sufficient controls in place to ascertain the Company’s consolidated financial statements properly reflect the change.
In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring an entity use the if-converted method and the effect of potential share settlement be included in diluted earnings per share calculations. This new standard will be effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of adopting this standard on the consolidated financial statements.
10

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
4.  Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

•Step 1: Identify the contract with the customer
•Step 2: Identify the performance obligations in the contract
•Step 3: Determine the transaction price
•Step 4: Allocate the transaction price to the performance obligations in the contract
•Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
The following is a description of principal activities from which the Company generates its revenue.
Product sales –The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Drug and dialysis concentrates products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time control of the product transfers to the customer.
The Company received upfront fees under five distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”), Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India, South Korea and Turkey, respectively, to determine regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”) are recognized as revenue at the point in time the estimated product sales under the agreement occur. 
For the business under the Company’s Distribution Agreement with Baxter (the “Baxter Agreement”) and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
In thousands of U.S. dollars ($) Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$193 $193 $— $834 $561 $273 
License Fee – Over time65 — 65 192 — 192 
Total Drug Products258 193 65 1,026 561 465 
Concentrates Products
Product Sales – Point-in-time17,953 16,619 1,334 51,035 46,334 4,701 
License Fee – Over time480 480 — 1,436 1,436 — 
Total Concentrate Products18,433 17,099 1,334 52,471 47,770 4,701 
Net Revenue$18,691 $17,292 $1,399 $53,497 $48,331 $5,166 
In thousands of U.S. dollars ($)Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$217 $217 $— $656 $656 $— 
License Fee – Over time62 — 62 179 — 179 
Total Drug Products279 217 62 835 656 179 
Concentrates Products
Product Sales – Point-in-time15,224 13,541 1,683 44,308 39,768 4,540 
License Fee – Over time485 485 — 1,456 1,456 — 
Total Concentrate Products15,709 14,026 1,683 45,764 41,224 4,540 
Net Revenue$15,988 $14,243 $1,745 $46,599 $41,880 $4,719 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousands of U.S. dollars ($)September 30, 2022December 31, 2021
Receivables, which are included in "Trade and other receivables"$7,367 $5,913 
Contract liabilities$6,729 $8,157 
There were no impairment losses recognized related to any receivables arising from the Company’s contracts with customers for the three and nine months ended September 30, 2022 and 2021.
For the three and nine months ended September 30, 2022 and September 30, 2021, the Company did not recognize any material bad-debt expense. There were no material contract assets recorded on the condensed consolidated balance sheet as of September 30, 2022 and December 31, 2021.  The Company does not generally accept returns of its concentrates products and no material reserve for returns of concentrates products was established as of September 30, 2022 or December 31, 2021. 
The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products
Transaction price allocated to remaining performance obligations
For the three and nine months ended September 30, 2022, revenue recognized from performance obligations related to prior periods was not material.
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced, and contracts with variable consideration related to undelivered performance obligations, totaled $6.7 million as of September 30, 2022. The amount relates primarily to upfront payments and consideration received from customers in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations having original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled minimum commitments related to the Baxter Agreement are product sales of $3.8 million as of September 30, 2022, which is amortized ratably through expiration of the Baxter Agreement on October 2, 2024.
11

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
5.  Investments - Available-for-Sale
Investments available-for-sale consisted of the following as of September 30, 2022 and December 31, 2021 (table in thousands):
September 30, 2022
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$14,578 $6 $(1)$1 $14,584 

December 31, 2021
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$9,143 $1 $— $14 $9,158 
The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements.
As of September 30, 2022 and December 31, 2021, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.
6.  Inventory
Components of inventory, net of reserves, as of September 30, 2022 and December 31, 2021 are as follows (table in thousands):
September 30,
2022		December 31,
2021
Raw Materials$4,074 $3,434 
Work in Process336 201 
Finished Goods1,803 1,964 
Total$6,213 $5,599 
As of September 30, 2022, the Company classified $1.2 million of inventory as non-current, all of which was related to the active pharmaceutical ingredient and raw materials for TRIFERIC®. As of September 30, 2022, the total TRIFERIC® inventory net of reserve was $1.2 million.
The $1.2 million net value of TRIFERIC® inventory consisted of $0.3 million of TRIFERIC® API with an estimated useful life extending through 2023, and $0.9 million of raw materials for TRIFERIC® with an estimated useful life of 25 years.
12

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
7.  Property and Equipment
As of September 30, 2022 and December 31, 2021, the Company’s property and equipment consisted of the following (table in thousands):
September 30,
2022		December 31,
2021
Leasehold Improvements$1,257 $1,204 
Machinery and Equipment5,985 5,864 
Information Technology & Office Equipment1,845 1,845 
Laboratory Equipment660 676 
9,747 9,589 
Accumulated Depreciation(7,483)(7,103)
Property and Equipment, net$2,264 $2,486 
Depreciation expense for both the three months ended September 30, 2022 and 2021 was $0.1 million. Depreciation expense for nine months end September 30, 2022 and 2021 was $0.4 million and $0.5 million, respectively.
13

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
8.  Accrued Liabilities
Accrued liabilities as of September 30, 2022 and December 31, 2021 consisted of the following (table in thousands):
September 30,
2022		December 31,
2021
Accrued Research & Development Expense$65 $366 
Accrued Compensation and Benefits3,006 1,791 
Accrued Unvouchered Receipts581 796 
Accrued Workers Compensation294 382 
Other Accrued Liabilities1,941 1,755 
Total Accrued Liabilities$5,887 $5,090 
9.  Deferred Revenue
In October 2014, the Company entered into the Baxter Agreement, which has a term of 10 years and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Distribution Agreement. The Company recognized revenue of approximately $0.5 million and $1.4 million for the three and nine months ended September 30, 2022, respectively. The Company recognized revenue of approximately $0.5 million and $1.5 million for the three and nine month ended September 30, 2021, respectively. Deferred revenue related to the Baxter Agreement totaled $3.8 million as of September 30, 2022 and $5.2 million as of December 31, 2021.
In 2016, the Company entered into a distribution agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $0.1 million and $0.2 million during each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Wanbang Agreement totaled $2.3 million as of September 30, 2022 and $2.5 million as of December 31, 2021.

In January 2020, the Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in India. In consideration for the license, the Company received an upfront fee of $0.1 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $7,500 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Sun Pharma Agreement totaled $72,500 and $80,000 as of September 30, 2022 and December 31, 2021, respectively.

In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize TRIFERIC® (dialysate) (ferric pyrophosphate citrate) in South Korea. In consideration for the license, the Company received an upfront fee of $0.2 million. In May 2022, Jeil Pharma obtained regulatory approval in South Korea and paid the Company $0.2 million in consideration of reaching the milestone. The upfront fee and milestone payments were recorded as deferred revenue and are being recognized as revenue based on the agreement term. The Company recognized revenue of $5,200 and $13,000 for the three and nine months ended September 30, 2022, respectively, and $2,500 and $7,500 for the three and nine months ended September 30, 2021, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.4 million and $0.2 million as of September 30, 2022 and December 31, 2021 respectively.

In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize TRIFERIC® (dialysate) and TRIFERIC® AVNU in Turkey. In consideration for the license, the Company received an upfront fee of $0.15 million. The upfront fee was recorded as deferred revenue and will be recognized as revenue based on the agreement term. The Company recognized revenue of $3,750 and $11,250 for each of the three and nine months ended September 30, 2022 and 2021, respectively. Deferred revenue related to the Drogsan Agreements totaled approximately $0.13 million and $0.15 million as of September 30, 2022 and December 31, 2021, respectively.
14

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
10.  Stockholders’ Equity

Reverse Stock Split
On May 9, 2022, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased.
Preferred Stock
On April 6, 2022, the Company and DaVita entered into the SPA, which provided for the issuance by the Company of up to $15 million of preferred stock to DaVita. On April 6, 2022, the Company issued 7,500 shares of Series X Preferred Stock for gross proceeds of $7.5 million. On June 2, 2022, the Company met the conditions for the Second Tranche through a Registered Direct and Private Placement Offering by raising $15 million in additional capital. As a result, on June 16, 2022 the Company issued an additional 7,500 shares of the Series X Preferred Stock to DaVita for gross proceeds of $7.5 million.

The Series X Preferred Stock was issued for a price of $1,000 per share (the "Face Amount"), subject to accretion at a rate of 1% per annum, compounded annually. If the Company’s common stock trades above $22.00 for a period of 30 calendar days, the accretion will thereafter cease.

The Series X Convertible Preferred Stock is convertible to common stock at rate equal to the Face Amount, divided by a conversion price of $11.00 per share (subject to adjustment for future stock splits, reverse stock splits and similar recapitalization events). As a result, each share of Series X Preferred Stock will initially convert into approximately 91 shares of common stock. DaVita’s right to convert to common stock is subject to a beneficial ownership limitation, which is initially set at 9.9% of the outstanding common stock, which limitation may be reset (not to exceed 19.9%) at DaVita’s option and upon providing prior written notice to the Company. In addition, any debt financing is limited by the terms of our Securities Purchase Agreement with DaVita. Specifically, until DaVita owns less than 50% of its investment, the Company may only incur additional debt in the form of a purchase money loan, a working capital line of up to $5 million or to refinance existing debt, unless DaVita consents.
Additionally, the Series X Preferred Stock has a deemed liquidation event and redemption clause which could be triggered if the sale of all or substantially all of the Company's assets relating to the Company's dialysis concentrates business line. Since the Series X Preferred Stock may be redeemed if certain assets are sold at the option of the holder, but is not mandatorily redeemable, the preferred stock has been classified as permanent equity and initially recognized at fair value of $15 million (the proceeds on the date of issuance) less issuance costs of $0.1 million, resulting in an initial value of $14.9 million. The Company will assess at each reporting period whether conditions have changed to now meet the mandatorily redemptive definition which could trigger liability classification.
As of September 30, 2022 and December 31, 2021, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 15,000 and nil shares of preferred stock issued and outstanding, respectively.
Common Stock
As of September 30, 2022 and December 31, 2021, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 11,152,673 and 8,544,225 shares issued and outstanding, respectively.
Controlled Equity Offering

On April 8, 2022, the Company entered into the Sales Agreement with Cantor Fitzgerald & Co. as Agent, pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended, pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the SEC on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022.

In May 2022, the Company sold 7,500 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $15,135, at a weighted average selling price of approximately $2.02. The Company paid $378 in commissions and offering fees related to the sale of shares of common stock.

Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).
Registered Direct Offering

On May 30, 2022, the Company entered into the RD Purchase Agreement with the Purchaser named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and pre-funded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.

A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrants to the extent the holder would own more than 9.99% of the Company’s outstanding common stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrant. The RD Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchaser and customary indemnification rights and obligations of the parties.

A total of 7,311,000 Pre-Funded Warrants remained outstanding as of September 30, 2022.
Private Placement

Also on May 30, 2022, concurrently with the Offering, the Company entered into the PIPE Purchase Agreement relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share.

As of September 30, 2022 9,900,990 PIPE Warrants and no Pre-Funded PIPE Warrants remained outstanding.

In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchaser, dated as of June 2, 2022 (the “RRA”). Pursuant to the RRA, the Company was required to prepare and file a registration statement with the SEC no later than July 1, 2022, and to use its reasonable best efforts to have the registration statement declared effective as promptly as possible, subject to certain specified penalties if timely effectiveness is not achieved. The Company filed a registration statement on June 22, 2022 which became effective on July 5, 2022.

The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses. Subject to certain ownership limitations, the PIPE Warrants are exercisable upon issuance.

The Company has accounted for the common stock related to the Offering and Private Placement as equity on the accompanying consolidated balance sheets as of September 30, 2022. The amount allocated to common stock was $2.0 million. This allocation is equal to the total proceeds of $15.0 million less the amount allocated to Warrants of $12.9 million and is also net of the direct and incremental costs associated with the Offering and Private Placement of $0.1 million. The Black-Scholes pricing model was used to calculate the value of Warrants relating to the Offering and Private Placement.
15

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
11.  Stock-Based Compensation
The Company recognized total stock-based compensation expense during the three and nine months ended September 30, 2022 and 2021 as follows (table in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Service-based awards:
Restricted stock units$46 $81 $84 $263 
Stock option awards130 315 401 1,050 
176 396 485 1,313 
Performance-based awards:
Restricted stock awards— — (391)(391)
Stock option awards— (35)— (364)
— (35)(391)(755)
Total$176 $361 $94 $558 
Performance Based Restricted Stock
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 20227,118 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 2022891 $62.70 
A summary of the Company’s restricted stock awards during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202113,345 $62.70 
Forfeited(6,227)$62.70 
Unvested at September 30, 20217,118 $62.70 
The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of September 30, 2022, unvested restricted stock awards of 891 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the resignation of the Company's Chief Development Officer on March 25, 2022. These forfeited awards reduced stock-based compensation expense by $0.4 million. As of September 30, 2021, unvested restricted stock awards of 7,118 were related to performance-based awards. The forfeited performance-based restricted stock awards of 6,227 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.
16

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Service-Based Restricted Stock Units
A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2022 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202229,289 $12.87 
Granted125,000 1.47 
Vested(23,515)11.33 
Forfeited(5,774)19.00 
Unvested at September 30, 2022125,000 $1.47 

A summary of the Company’s service-based restricted stock units during the nine months ended September 30, 2021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 202124,136 $28.60 
Granted28,186 9.90 
Vested(20,134)26.18 
Forfeited(1,073)52.91 
Unvested at September 30, 202131,115 $12.87 
The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $46,193 and $83,607 was recognized for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense of $0.1 million and $0.3 million was recognized for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, the unrecognized stock-based compensation expense was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year.
Service-Based Stock Options
The fair value of the service-based stock options granted for the nine months ended September 30, 2022 were based on the following assumptions:
September 30,
2022
Exercise price
$1.28 - $1.66
Expected stock price volatility
76.2% - 78.5%
Risk-free interest rate
1.97% - 3.44%
Term (years)
5.5 - 6
17

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2022 is as follows:
Shares
Underlying
Options		Weighted
Average Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding at January 1, 2022528,591 $32.01 7.5$— 
Granted898,659 1.49 5.5— 
Forfeited(30,093)15.11 — — 
Expired(85,466)82.09 — — 
Outstanding at September 30, 20221,311,691 $8.23 9.1$— 
Exercisable at September 30, 2022243,973 $29.31 6.9$— 
A summary of the Company’s service-based stock option activity for the nine months ended September 30, 2021 is as follows:
Shares
Underlying
Options		Weighted
Average Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding at January 1, 2021519,814 $50.05 6.6$— 
Granted170,197 9.79 6.0— 
Forfeited(35,025)25.30 — — 
Expired(121,202)78.76 — — 
Outstanding at September 30, 2021533,784 $32.45 7.7$— 
Exercisable at September 30, 2021230,858 $54.56 5.8$— 
The aggregate intrinsic value in the table above is calculated as the difference between the closing price of the Company's common stock and the exercise price of the stock options that had strike prices below the closing price.
During the nine months ended September 30, 2022, the Company granted stock options to purchase up to 898,659 shares of common stock to certain employees. During the nine months ended September 30, 2022, 30,093 shares were forfeited and 85,466 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.
Stock-based compensation expense recognized for service-based stock options was $0.1 million and $0.4 million for the three and nine months ended September 30, 2022, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $1.0 million for the three and nine months ended September 30, 2021, respectively. As of September 30, 2022, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $1.4 million, which is expected to be recognized over an estimated weighted average remaining term of 3.6 years.
18

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
12.  Licensing Agreements
Product License Agreements
The Company is a party to a Licensing Agreement between the Company and Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our TRIFERIC® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, a former Officer of the Company. Pursuant to the MSA, the parties entered into three additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak. As of September 30, 2022, the Company has accrued $85,400 relating to certain IP reimbursement expenses and certain sublicense royalty fees and is included within accrued liabilities on the condensed consolidated balance sheet.
Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales by the Company of products developed under the license, which includes the Company’s TRIFERIC® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. TRIFERIC®, dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN TRIFERIC®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain TPN products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sublicensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sublicensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
The potential milestone payments are not yet considered probable, and no milestone payments have been accrued at September 30, 2022.
19

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
13.  Leases
Rockwell leases its production facilities and administrative offices as well as certain equipment used in its operations including leases on transportation equipment used in the delivery of its products. The lease terms range from monthly to six years. Rockwell occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2024. Rockwell also occupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2026. In addition, Rockwell occupied 4,100 square feet of office space in Hackensack, New Jersey under a lease expiring on October 31, 2024. This lease was subleased on December 15, 2021 with an expiration date of October 31, 2024.
At September 30, 2022, the Company had operating and finance lease liabilities of $7.2 million and right-of-use assets of $6.9 million, which are included in the consolidated balance sheet.
At December 31, 2021, the Company had operating lease liabilities of $7.9 million and right-of-use assets of $7.7 million, which are included in the consolidated balance sheet.
The following summarizes quantitative information about the Company’s operating leases (table in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Operating leases
Operating lease cost$410 $457 $1,289 $1,309 
Variable lease cost101 94 287 286 
Operating lease expense511 551 1,576 1,595 
Finance leases
Amortization of right-of-use assets141 73 424 184 
Interest on lease obligations44 22 136 55 
Finance lease expense185 95 560 239 
Short-term lease rent expense5 4 14 12 
Total rent expense$701 $650 $2,150 $1,846 
Other information
Operating cash flows from operating leases$427 $444 $1,338 $1,298 
Operating cash flows from finance leases$44 $22 $136 $56 
Financing cash flows from finance leases$121 $59 $359 $152 
Right of use assets exchanged for operating lease liabilities$768 $718 $768 $4,089 
Right of use assets exchanged for finance lease liabilities$— $588 $— $1,365 
Weighted-average remaining lease term – operating leases3.23.73.23.7
Weighted-average remaining lease term – finance leases4.75.54.75.5
Weighted-average discount rate – operating leases6.4 %6.3 %6.4 %6.3 %
Weighted-average discount rate – finance leases6.4 %5.9 %6.4 %5.9 %
Future minimum rental payments under operating lease agreements are as follows (in thousands):
OperatingFinance
Year ending December 31, 2022 (remaining)$434 $165 
Year ending December 31, 20231,692 669 
Year ending December 31, 20241,404 672 
Year ending December 31, 2025937 676 
Year ending December 31, 2026310 666 
Remaining future payments120 311 
Total$4,897 $3,159 
Less present value discount(467)(426)
Operating and finance lease liabilities$4,430 $2,733 
20

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
14. Loan and Security Agreement

On March 16, 2020, the Company and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company is no longer eligible to draw on a second tranche of $5.0 million or a third tranche of $7.5 million, which were tied to the achievement of certain milestones by a specific date. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.
In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $18.15 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 43,388 shares of the Company’s common stock at an exercise price of $18.15 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.

The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the three months ended September 30, 2022 and 2021, interest expense amounted to $0.4 million and $0.6 million, respectively. For the nine months ended September 30, 2022 and 2021, interest expense amounted to $1.2 million and $1.8 million, respectively.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds are used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of TRIFERIC®, with the latter beginning with the period ending December 31, 2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants in the future. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity.

In September 2021, the Company entered into an amendment to the Loan Agreement in which the Company, in exchange for Innovatus lowering the sales covenants, agreed to (i) prepay an aggregate principal amount of $7,500,000 in ten installments commencing on December 1, 2021; (ii) pay an additional prepayment premium of 5% on prepaid amounts if the Company elects to prepay all outstanding Term Loans on or before September 24, 2023 and (iii) maintain minimum liquidity of no less than $5,000,000 if the aggregate principal amount of Term Loans is greater than $15,000,000 pursuant to the liquidity covenant in the Loan Agreement.

On March 31, 2022, the Collateral Agent and Lenders consented to the delivery to Collateral Agent and Lenders of its annual audited financial statements for the fiscal year 2021 by April 15, 2022 as opposed to within 90 days of December 31, 2021, as required pursuant to Loan Agreement.

As of September 30, 2022, the Company was in compliance with all covenants under the Loan Agreement.

As of September 30, 2022, the outstanding balance of the Term Loan was $14.1 million, net of unamortized issuance costs and discount of $0.9 million.

The following table reflects the schedule of principal payments on the Term Loan as of September 30, 2022 (in thousands):
Principal Payments
2022$1,000 
20236,000 
20246,000 
20252,000 
$15,000 

21

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
15. Insurance Financing Note Payable
On June 2, 2022, the Company entered into a short-term note payable for $1.5 million, bearing interest at 5.40% per annum to finance various insurance policies. Principal and interest payments related to this note began on July 3, 2022 and were paid on a straight-line amortization over 9 months with the final payment due on March 3, 2023. As of September 30, 2022, the Company's insurance note payable balance was $1.0 million.
16. Subsequent Events
On October 28, 2022, 480,000 Pre-Funded Warrants to purchase common stock pursuant the SPA entered into on May 30, 2022 were exercised. The exercise price of each Pre-Funded Warrant is $0.0001 per share and resulted in gross proceeds of $48.00 (See Note 10 for more detail on the SPA).
On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products and provided customer service and order delivery to nearly all United States customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products to dialysis clinics throughout the United States and around the world.
Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.
On November 10, 2022, the Company entered into a Second Amendment to the Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.
Separation of Chief Financial Officer
On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.



22

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to “Rockwell,” the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.
Forward-Looking Statements
We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC.  We may also make forward-looking statements in our press releases or other public or shareholder communications.  Our forward-looking statements are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our ability to continue as a going concern; our ability to develop Ferric Pyrophosphate Citrate (“FPC”) for other indications; our ability to successfully execute on our business strategy and development of new indications; our ability to raise additional capital; our ability to renegotiate certain terms of our supply contracts; our ability to successfully implement certain cost containment and cost-cutting measures; our ability to achieve profitability and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.
While we believe our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made.  Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different.  Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Form 10-K for the year ended December 31, 2021 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.
Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position.  There can be no assurance future results will meet expectations.  Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.
Overview
Rockwell Medical is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney.
Rockwell is a revenue-generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed at a freestanding outpatient dialysis center, at a hospital-based outpatient center, or in a patient’s home. This represents a large market opportunity for which Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under cGMP regulations at its three facilities in Michigan, Texas, and South Carolina totaling approximately 175,000 square feet, and manufactures mixers in its Iowa facility. Rockwell delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally utilizing its own delivery trucks and third-party carriers. Rockwell has developed a core expertise in manufacturing and delivering hemodialysis concentrates, and has built a longstanding reputation for reliability, quality, and excellent customer service.
Rockwell has a proprietary parenteral iron product, TRIFERIC® (ferric pyrophosphate citrate, "FPC"), which is indicated to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. While Rockwell has discontinued commercialization of TRIFERIC® in the United States, the Company has established several international partnerships with companies seeking to develop and commercialize TRIFERIC® outside the United States and is working closely with these international partners to develop and commercialize TRIFERIC® in their respective regions.
Rockwell continues to evaluate the viability of its FPC platform and FPC's potential to treat iron deficiency and iron deficiency anemia and for acute heart failure.
Rockwell’s strategy is focused on growing the Company's revenue-generating business, which currently includes hemodialysis concentrates and international partnerships for TRIFERIC® and achieving profitability in 2024 to put the Company in a stronger and more stable financial position.
Hemodialysis Concentrates Business: Rockwell is the second largest supplier of life-sustaining hemodialysis concentrates products to dialysis clinics in the United States. Our hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. A key element of our dialysis business strategy going forward is to improve the strength of our concentrates business. We believe we can achieve this by growing our business through the addition of new customers, expanding our territory coverage, increasing the efficiency by which Rockwell produces its products, and pricing our products appropriately to drive profitability.
Prior to the second quarter of 2022, Rockwell's concentrates business operated at a loss. This loss was accelerated due to inflation, which has increased our manufacturing and operating costs. We undertook discussions with our largest customers to renegotiate our existing supply contracts to improve the profitability of this business line. On April 6, 2022, we amended our agreement with our long-time partner, DaVita, Inc. ("DaVita"), a leading provider of kidney care, to enable us to stabilize our concentrates business. The amended agreement provides a stronger financial arrangement which encompasses pricing, cost share, cost cutting, and joint efforts to improve supply chain, all of which is intended to drive Rockwell’s concentrates business to operate profitably in the future. In addition to the amended agreement, DaVita invested $15 million in preferred stock in two equal tranches. The first tranche of $7.5 million was funded on April 7, 2022. The second tranche of $7.5 million was funded on June 16, 2022. We continue to review our entire supply chain to identify opportunities for improvement, prioritizing initiatives that will have the largest impact on long-term efficiency, profitability, and growth.
On November 9, 2022, Rockwell reacquired its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014. Exclusivity and other provisions associated with the distribution agreement terminated November 9, 2022 and the remaining operational elements of the agreement terminate December 31, 2022. Under the exclusive distribution agreement, Baxter distributed and commercialized Rockwell’s hemodialysis concentrates products in the United States and certain other countries. Rockwell manufactured all hemodialysis concentrates products and provided customer service and order delivery to nearly all U.S. customers. Following the reacquisition of these rights, Rockwell will now be able to sell its hemodialysis concentrates products directly to dialysis clinics throughout the United States and around the world. Additionally, Rockwell will now be able to independently price its products, eliminate costs associated with manufacturing covenants, improve manufacturing efficiencies, realize the full benefits from those improvements, and develop, in-license, or acquire new products to develop a broader kidney care products portfolio. This is expected to improve Rockwell's overall profitability and set the Company on a positive growth trajectory. Collectively, this affords Rockwell the opportunity to expand its leadership position within a large market opportunity, which currently is valued at $380 million and is anticipated to grow to approximately $500 million by 2026 in the United States alone.
Rockwell will pay Baxter a fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. To ensure that customer needs continue to be met after January 1, 2023, Baxter and Rockwell are working closely together to transition customers’ purchases of Rockwell’s hemodialysis concentrates from Baxter to Rockwell.
TRIFERIC®: Our first two branded products from our FPC platform, TRIFERIC® (dialysate) and TRIFERIC® AVNU (intravenous), are indicated to maintain hemoglobin in patients undergoing hemodialysis. We began commercializing TRIFERIC® and TRIFERIC® AVNU in the United States in the second half of 2019 and in early 2021, respectively. In addition, Rockwell established six international partnerships to develop and commercialize TRIFERIC® in China, India, Korea, Turkey, Peru and Chile.
Rockwell undertook a strategic review of TRIFERIC®'s viability in the United States. TRIFERIC® was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire TRIFERIC® despite Rockwell's significant effort to partner the program, the Company discontinued its New Drug Applications (“NDAs”) for TRIFERIC® and TRIFERIC® AVNU in the United States. Sustaining
TRIFERIC® commercially in the United States resulted in a loss to Rockwell of approximately $2 million to $3 million, annually. The decision to discontinue the NDAs was not made lightly as the Company realizes the direct impact this action has on patients currently using the products. TRIFERIC® and its approved presentations were not discontinued for safety reasons.
Rockwell will continue to support its partners outside the United States. Rockwell has six international partnerships in China, India, Korea, Turkey, Peru, and Chile with organizations who have exclusive license agreements to develop and commercialize TRIFERIC® outside the United States.  Partnering in these regions allows us to better leverage the development, regulatory, commercial presence and expertise of business partners to increase sales of our products throughout the world. We believe there is still significant opportunity for TRIFERIC® internationally and will work diligently to support our partners, which requires minimal financial commitment from Rockwell and provides us with potential for near- and long-term revenue. We continue to pursue international licensing opportunities in other countries and regions.
Research and Development Pipeline:
FPC for Home Infusion is Rockwell's follow-up to TRIFERIC® and utilizes the FPC platform in the home infusion setting.
In late 2021, Rockwell filed an Investigational New Drug (“IND”) application with the United States Food and Drug Administration (“FDA”) for the treatment of iron deficiency anemia in patients, who are receiving medications in the home infusion setting. During the second quarter 2022, Rockwell provided the FDA with supplemental data to be used in Rockwell’s clinical studies and to clinically support the Company’s IND application for home infusion. The FDA placed this program on Clinical Hold and requested that additional data related to the microbiology and short-term stability of this formulation be provided to support the application. During the third quarter of 2022, Rockwell conducted a microbiological and short-term stability study of FPC for Home Infusion, in accordance with FDA guidance, to support the Company’s IND application. Preliminary results from the microbiology and short-term stability study indicated that the program would likely not meet the FDA’s requirements to support the IND application and would require significant capital expenditure and resources to support additional re-formulation work and conduct a Phase 2 study. As a result, Rockwell has put development work associated with FPC for Home Infusion on hold.
Rockwell is also exploring FPC’s impact on the treatment of hospitalized acute heart failure patients, which affects more than one million people in the United States annually. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics during hospitalization. This effect could help patients recover faster potentially resulting in shorter hospital stays and fewer 30-day re-admissions. If realized, these outcomes could translate into a meaningful reduction in healthcare costs and human suffering. Rockwell submitted a pre-IND meeting request to the FDA and expects to meet with the FDA before the end of this year. Depending on the feedback from FDA, Rockwell will determine the path forward for this program.

Reverse Stock Split
On May 9, 2022, the Company's stockholders authorized the Company's Board of Directors to effect a reverse stock split of all outstanding shares of common stock, warrants and options. The Board of Directors subsequently approved the implementation of a reverse stock split as a ratio of one-for-eleven shares, which became effective on May 13, 2022. The Company’s outstanding stock options were also adjusted to reflect the one-for-eleven reverse stock split of the Company’s common stock. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series X convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to the account for the effect of the reverse stock split for the three- and nine-month periods ended September 30, 2022 and 2021, respectively, and the balance sheet at September 30, 2022 and December 31, 2021.
23

Results of Operations for the Three Months Ended September 30, 2022 and 2021
The following table summarizes our operating results for the periods presented below (dollars in thousands):
For the Three Months Ended September 30,
2022% of Revenue2021% of Revenue% Change
Net Sales$18,691 $15,988 16.9 %
Cost of Sales17,914 95.8 %16,317 102.1 %9.8 
Gross Profit (Loss)777 4.2 (329)(2.1)(336.2)
Research and Product Development469 2.5 1,221 7.6 (61.6)
Selling and Marketing762 4.1 1,541 9.6 (50.6)
General and Administrative3,254 17.4 3,881 24.3 (16.2)
Operating Loss$(3,708)(19.8)%$(6,972)(43.6)%(46.8)%
Net Sales
During the three months ended September 30, 2022, our net sales were $18.7 million compared to net sales of $16.0 million during the three months ended September 30, 2021. The increase of $2.7 million was primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers.
Gross Profit (Loss)
Cost of sales during the three months ended September 30, 2022 was $17.9 million, resulting in gross profit of $0.8 million during the three months ended September 30, 2022, compared to cost of sales of $16.3 million and a gross loss of $0.3 million during the three months ended September 30, 2021. Gross profit increased by $1.1 million primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers. As a result, the Company expects an improvement in margins for the remainder of 2022.
Research and Product Development Expense
Research and product development expenses were $0.5 million and $1.2 million for the three months ended September 30, 2022 and 2021, respectively. Research and product development expenses decreased by $0.7 million due to greater cash management over project costs, a reduction in headcount and shifting our project timelines as noted above in the "Overview and Recent Developments" section above.
Selling and Marketing Expense
Selling and marketing expenses were $0.8 million during the three months ended September 30, 2022, compared with $1.5 million during the three months ended September 30, 2021. The decrease of $0.7 million is due to reduced marketing spend for our TRIFERIC® products and previous headcount reduction. See "Overview and Recent Developments" for more detail.
General and Administrative Expense
General and administrative expenses were $3.3 million during the three months ended September 30, 2022, compared with $3.9 million during the three months ended September 30, 2021. The decrease is primarily due to greater cash management and the reduced usage of outside agencies.
Other Income (Expense)
Other income for the three months ended September 30, 2022 and 2021 was negligible. Other expense for the three months ended September 30, 2022 was $0.5 million of interest expense related to our debt facility (see Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility). Other expense for the three months ended September 30, 2021 was $0.6 million of interest expense related to our debt facility.
24

Results of Operations for the Nine Months Ended September 30, 2022 and 2021
The following table summarizes our operating results for the periods presented below (dollars in thousands):
For the Nine Months Ended September 30,
2022% of Revenue2021% of Revenue% Change
Net Sales$53,497 $46,599 14.8 %
Cost of Sales51,760 96.8 %46,788 100.4 %10.6 
Gross Profit (Loss)1,737 3.2 (189)(0.4)(1,019.0)
Research and Product Development2,963 5.5 5,445 11.7 (45.6)
Selling and Marketing1,743 3.3 4,860 10.4 (64.1)
General and Administrative11,845 22.1 11,483 24.6 3.2 
Operating Loss$(14,814)(27.7)%$(21,977)(47.2)%(32.6)%
Net Sales
During the nine months ended September 30, 2022, our net sales were $53.5 million compared to net sales of $46.6 million during the nine months ended September 30, 2021. The increase of $6.9 million was primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers.
Gross Profit (Loss)
Cost of sales during the nine months ended September 30, 2022 was $51.8 million, resulting in gross profit of $1.7 million during the nine months ended September 30, 2022, compared to cost of sales of a $46.8 million and a gross loss of $0.2 million during the nine months ended September 30, 2021. Gross profit increased by $1.9 million primarily due to the restructuring of our supply contract with DaVita and increased pricing to other customers. As a result, the Company expects an improvement in margins for the remainder of 2022.
Research and Product Development Expense
Research and product development expenses were $3.0 million for the nine months ended September 30, 2022, compared with $5.4 million during the nine months ended September 30, 2021. This decrease of $2.4 million is primarily due to the resignation of our Chief Development Officer, headcount reductions, greater cash management over projects costs and shifting our project timelines as noted above in the "Overview and Recent Developments" section above.
Selling and Marketing Expense
Selling and marketing expenses were $1.7 million during the nine months ended September 30, 2022, compared with $4.9 million during the nine months ended September 30, 2021. The decrease of $3.2 million is primarily due to reduced marketing spend for our TRIFERIC® products and headcount reductions. See "Overview and Recent Developments" for more detail.
General and Administrative Expense
General and administrative expenses were $11.8 million during the nine months ended September 30, 2022, compared with $11.5 million during the nine months ended September 30, 2021. The increase of $0.3 million is due primarily to a one-time charge related to the severance agreement for our former Chief Executive Officer offset by reductions in the use of outside agencies.
Other Income (Expense)
Other income for the nine months ended September 30, 2022 and 2021 was $(10,000) and $17,000, respectively. Other expense for the nine months ended September 30, 2022 was $1.5 million of interest expense related to our debt facility (see Note 14 for more information on our debt facility). Other expense for the nine months ended September 30, 2021 was $1.8 million of interest expense related to our debt facility.
25

Liquidity and Capital Resources
As of September 30, 2022, we had approximately $27.6 million of cash, cash equivalents and investments available-for-sale, and working capital of $23.0 million. Net cash used in operating activities for the nine months ended September 30, 2022 was approximately $16.8 million.
On April 6, 2022, the Company and DaVita entered into an amendment (the "Amendment") to the Products Purchase Agreement, dated July 1, 2019, under which the Company supplies DaVita with certain dialysis concentrates. Under the Amendment, the Company and DaVita agreed to certain price increases, effective May 1, 2022, as well as the pass-through of certain inflationary costs, determined on a quarterly basis. The Amendment also requires the Company to implement certain cost containment and cost-cutting measures. The Amendment contains certain covenants with respect to the Company’s ongoing operations, including a minimum cash covenant of $10 million, or we will be in default under the Products Purchase Agreement. An event of default could result in termination of that agreement.
On April 6, 2022, the Company and DaVita entered into a Securities Purchase Agreement (the “SPA”), pursuant to which the Company issued $15 million of preferred stock to DaVita in two separate tranches. The Company initially issued 7,500 shares of a newly designated series of preferred stock, which is designated “Series X Convertible Preferred Stock” (the “Series X Preferred Stock”) for gross proceeds of $7.5 million. On June 15, 2022, the Company issued to DaVita an additional 7,500 shares of Series X Preferred Stock in a second closing (the “Second Tranche”) for an additional $7.5 million. The Second Tranche was conditioned upon the Company raising an additional $15.0 million in capital within a certain timeline, which took place on June 2, 2022.
On April 8, 2022, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $12,200,000 of shares of Company’s common stock through the Agent. The offering and sale of such shares has been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-259923) (the “Registration Statement”), which was originally filed with the Securities and Exchange Commission (“SEC”) on September 30, 2021 and declared effective by the SEC on October 8, 2021, the base prospectus contained within the Registration Statement, and a prospectus supplement that was filed with the SEC on April 8, 2022. During the quarter ended September 30, 2022, no sales were made pursuant to the Sales Agreement. Approximately $12.2 million remains available for sale under the ATM facility. Under the RD Purchase Agreement and the PIPE Purchase Agreement discussed below, the Company has agreed not to make any sales under any at-the-market offering facility, including pursuant to the Sales Agreement, until at least January 1, 2023 (or until such later time when the Company is permitted to make additional sales under Instruction I.B.6 to Form S-3).
On May 30, 2022, the Company entered into a Securities Purchase Agreement (the “RD Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 844,613 shares of its common stock at price of $1.39 per share, and prefunded warrants to purchase up to an aggregate of 7,788,480 shares of common stock (the “Pre-Funded Warrants” and the shares of common stock underlying the Pre-Funded Warrants, the “Warrant Shares”). The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share.
Also on May 30, 2022, concurrently with the Offering, the Company entered into a Securities Purchase Agreement with the Purchaser (the “PIPE Purchase Agreement”) relating to the offering and sale (the “Private Placement”) of warrants to purchase up to a total of 9,900,990 shares of common stock and pre-funded warrants to purchase up to a total of 1,267,897 shares of common stock (the “PIPE Warrants”). Each warrant was sold at a price of $0.125 per underlying warrant share and is exercisable at an exercise price of $1.39 per share. The purchase price of each Pre-Funded Warrant was equal to the price at which a share of common stock was sold to the public in the Offering, minus $0.0001, and the exercise price of each prefunded warrant is $0.0001 per share. The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
The Offering and the Private Placement closed on June 2, 2022. The net proceeds to the Company from the Offering and the Private Placement were approximately $14.9 million, after deducting fees and expenses.
Based on the currently available working capital, and capital raises described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
The Company may require additional capital to sustain its operations and make the investments it needs to execute its strategic plan. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume such financing will be available on favorable terms, if at all.
In addition, the Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the date of this report, the Company is in compliance with all covenants (See Note 14 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on our debt facility).

The COVID-19 pandemic and resulting domestic and global disruptions, particularly in the supply chain and labor market, among other areas, have adversely affected Rockwell's business and operations, including, but not limited to, the Company's sales and marketing efforts and its research and development activities, the Company's plant and transportation operations, and the operations of third parties upon whom Rockwell relies. The Company's international business development activities may also continue to be negatively impacted by COVID-19.

The COVID-19 pandemic and the resulting global disruptions and recent inflationary pressures have caused significant volatility in financial and credit markets. Rockwell has utilized a range of financing methods to fund its operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding, refinancing, or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect the Company's liquidity and capital resources in the future.

General
The actual amount of cash we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial operations in the United States and internationally (with partners); the timing and magnitude of cash received from product sales; the timing and expenditures associated with the development programs including our FPC technology; and the costs associated with our manufacturing and transportation operations related to our concentrate business.
We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance we will be able to secure additional capital or funding on acceptable terms, or if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions.
We believe our ability to fund our activities in the long term will be highly dependent upon 1) our ability to execute on the growth strategy of our hemodialysis concentrates business, 2) our ability to achieve profitability, and 3) our ability to identify, develop, in-license, or acquire new products in developing our renal care product portfolio. All of these strategies are subject to significant risks and uncertainties such that there can be no assurance we will be successful in achieving them. If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.
Cash Used in Operating Activities
Net cash used in operating activities was $16.8 million for the nine months ended September 30, 2022 compared to net cash used in operating activities of $24.5 million for the nine months ended September 30, 2021. The decrease in cash used from operating activities during the current period was primarily due to an increase in net income, offset by changes in current balance sheet accounts in the ordinary course of business of approximately $3.1 million, including an increase in net account receivable of $1.5 million, decrease in other assets of $2.1 million, decrease in lease liability of $1.4 million and decrease in deferred revenue of $1.4 million.
Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities was $5.6 million during the nine months ended September 30, 2022 compared to net cash used in investing activities of $0.2 million for the nine months ended September 30, 2021. The net cash provided by investing activities during the nine months ended September 30, 2022 was primarily due to sales and purchase of available-for-sale investments during the year.
Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities was $22.1 million during the nine months ended September 30, 2022 compared to the net cash used in financing activities of $0.6 million for the nine months ended September 30, 2021. The net cash provided during the nine months ended September 30, 2022 was primarily due to multiple equity raises (See Note 10), offset by payments on the Company's debt and short term note payable.
Contractual Obligations and Other Commitments

See Note 12 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for additional disclosures. There have been no other material changes from the Contractual Obligations and Other Commitments disclosed in Note 14 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.
26

Critical Accounting Policies and Significant Judgments and Estimates
Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2021. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021.
Recently issued and adopted accounting pronouncements:
We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 to the condensed consolidated financial statements included elsewhere in this Form 10-Q.
Item 3.  Quantitative and Qualitative Disclosures about Market Risk

Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.
Item 4.  Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure material information required to be disclosed in our reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management was required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.
Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures were effective as of September 30, 2022.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27

PART II – OTHER INFORMATION
Item 1.  Legal Proceedings
We may be involved in certain routine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.
Item 1A. Risk Factors
Our business is subject to various risks, including those described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2021 under "Item 1A - Risk Factors" except as noted below.
Our reacquisition of distribution rights for our concentrates products from Baxter through the termination of our Exclusive Distribution Agreement has many attendant risks and may not result in the financial outcome we expect.
We recently terminated our Exclusive Distribution Agreement with Baxter and reacquired the distribution rights related to our concentrates products for Baxter’s portfolio of clinics. Our Distribution Agreement with Baxter enabled us to charge Baxter an amount above cost for our concentrates products, while limiting us to a capped percentage of sales for the transportation costs associated with delivering those products. When we assume full responsibility for selling and delivering our concentrates products to Baxter customers and any other customers we may add, we will bear all financial and other risk associated with the business. We may lose former Baxter customers if we need to increase the prices of our concentrates products due to rising costs or for other reasons. In addition, since we agreed to charge these customers a fixed cost through the transition period which ends on December 31, 2022 (and for a certain portfolio of customers, through March 31, 2023), we may lose money if those fixed costs do not cover our actual costs. We also may be unable to renegotiate unprofitable contracts with certain customers. Each of these scenarios could result in the business we reacquired generating less revenue or less profit than we expect and could adversely impact our financial condition or results of operations.
Unfavorable weather, economic conditions or supply shortages could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general weather conditions, as well as conditions in the United States and global economy and in the global financial markets. A severe weather or other geological event in our locations or those of our suppliers, or prolonged economic downturn or persistent inflation have and could continue to result in a variety of risks to our business, including our ability to recover our costs or to raise additional capital when needed on acceptable terms, if at all. In addition, weather-related events may jeopardize our ability to deliver our products as required by our contracts. For example, after Hurricane Ian severely damaged parts of the Florida Gulf Coast, many roads and bridges were destroyed. While we were able to make our deliveries after the storm, that may not always be the case. A weak or declining United States or global economy could also strain our suppliers, possibly resulting in supply disruption. In addition, due to macro-economic conditions in the global economy, there have been shortages in raw materials, parts and fuel that we need to run our business. Recently, our suppliers have experienced shortages in bicarbonate and acid, which are components of our dialysis concentrates, and parts needed for our equipment to make certain of our products. Diesel fuel is also in short supply in the United States and our delivery trucks run on diesel. While we have been able to minimize the impact of these disruptions to date, there can be no assurance that will continue. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.
We have been and may continue to be affected materially and adversely by increases in raw material and transportation costs and may be unable to recover certain costs due to provisions in our material contracts.
A significant portion of our costs relates to chemicals and other raw materials and transportation, which such costs are out of our control, and we may not be able to recover a portion of such costs due to provisions in our material contracts with
Baxter and DaVita. The costs of chemicals and other raw materials are subject to price volatility based on supply and demand and are highly influenced by the overall level of economic activity in the United States and abroad.
These costs have tended to rise from year to year and are likely to continue to rise in the future. In the past year, raw materials costs have increased significantly, due to short supply and excess demand. Transportation also comprises a significant portion of our costs. We have been adversely affected by a general shortage in commercial truckers in the United States and significant increases in labor and fuel costs. In addition, as mentioned above, there is now a nationwide shortage of diesel fuel in the United States, which we use to run our delivery trucks. If that shortage is not rectified, the cost of diesel fuel could rise or diesel fuel could be unavailable and we would need to find another way to deliver our products to clinics. If we are unable to do so, we could be in breach of our contracts.
Our Product Purchase Agreement (“Product Agreement”) with DaVita provides for a fixed price to DaVita, with limited increases from year to year, regardless of the increases in raw materials costs. As a result, we have in the past been unable to fully recover our costs for the products we sell to DaVita (including transportation costs). This has had and could in the future have a material and adverse impact on our financial position. On April 6, 2022, we entered into an amendment to the Products Purchase Agreement under which we agreed to a price increase, effective May 1, 2022, as well as the pass-through of certain costs, determined on a quarterly basis. Certain costs are subject to a cap. If our costs exceed those caps, we may be unable to fully recover our costs or if costs increase in excess of an overall cap, the Products Purchase Agreement may be subject to termination by DaVita.
We expect that if we continue to be subject to the limitations in the agreements with our customers, the increasing costs may continue to negatively impact our profit margins and materially and adversely affect our financial position.
We may become the target of litigation, which is costly and time-consuming to defend.
We have in the past been subject to litigation and it is possible that legal proceedings could be brought against us in the future based upon decisions we make regarding our strategy or otherwise. Litigation can be costly and time-consuming and the results of complex legal proceedings are difficult to predict. These lawsuits assert types of claims that, if resolved against us, could give rise to substantial damages, and an unfavorable outcome or settlement of these lawsuits, or any future lawsuits, could have a material adverse effect on our business, financial condition, results of operations and/or stock price. Even if any future lawsuits are not resolved against us, the costs of defending such lawsuits may be material to our business and our operations. Moreover, these lawsuits may divert our Board and our management’s attention from the operation of our business.
Current and future legislation may increase the difficulty and cost for us, and any collaborators, to obtain marketing approval of and commercialize our drug candidates and affect the prices we, or they, may obtain.
Heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare therapies, which could result in reduced demand for our product candidates or additional pricing pressures. Most recently, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (“IRA”), which, among other provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. We cannot be sure whether additional legislation or rule making related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.
Our revenue growth and profitability projections are based on various assumptions that may not come to fruition.
Our revenue growth and profitability projections are subject to many assumptions regarding our future operations, including that we are successful in expanding to new territories, that we successfully develop and launch new product offerings, that we are able to increase our prices to keep up with inflation, and that we do not experience significant disruptions to the manufacturing or distribution of our products, among other assumptions. If we are unsuccessful in one or more of those efforts, we may not be able to achieve our projected growth and profitability.
28

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
Amended Bylaws
On November 9, 2022, the Board of Directors of Rockwell adopted Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately. The amendments effected through the Amended Bylaws address, among other things, (i) requirements and procedures for annual and special meetings of stockholders, (ii) advance notice requirements for stockholder submission of proposals and director nominations, and (iii) requirements regarding the information stockholders must submit and representations stockholders must make in connection with stockholder proposals and director nominations. The Amended Bylaws also effected certain other administrative, modernizing, clarifying, and conforming changes.
The foregoing general description of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws set forth in Exhibit 3.1 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
Loan Agreement Amendment
On November 10, 2022, the Company entered into the Second Amendment to Loan and Security Agreement (the “Second Amendment”) dated as of November 14, 2022 with Innovatus, which further amended the Loan Agreement. Pursuant to the Second Amendment, the Company (i) shall prepay an aggregate principal amount of $5.0 million in Term Loans (as defined in the Loan Agreement) in one installment on November 14, 2022; (ii) shall pay interest only payments until September 2023 at which time will resume scheduled debt payments.
The foregoing general description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment set forth in Exhibit 10.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.
Baxter Termination
On November 9, 2022, Rockwell entered into a Distribution Termination and Acquisition Agreement with Baxter (the “Baxter Termination Agreement”) to reacquire full distribution rights to its hemodialysis concentrates products and has agreed to concurrently terminate the exclusive distribution agreement dated October 2, 2014. Rockwell will pay Baxter a nominal fee for the reacquisition of its distribution rights. This fee will be payable in two equal installments on January 1, 2023 and April 1, 2023. See Note 16 to the condensed consolidated financial statements included elsewhere in this Form 10-Q for more information on the agreement with Baxter.
The foregoing general description of the Baxter Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Baxter Termination Agreement.
Separation of Chief Financial Officer
On November 10, 2022, the Board of Directors of Rockwell terminated the employment of Russell Skibsted as Chief Financial Officer of the Company, effective immediately. The termination of employment of Mr. Skibsted by the Company without cause entitles Mr. Skibsted to severance in accordance with the Employment Agreement, dated September 15, 2020, by
and between the Company and Mr. Skibsted (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. In connection with Mr. Skibsted’s termination, the Board of Directors appointed Mark Strobeck, the Company’s Chief Executive Officer, as interim principal financial officer.
29

Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No.Description
3.1 *
10.1 +*
10.2 +*
10.3 *
31.1*
32.1**
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema
101.CAL*XBRL Taxonomy Extension Calculation Linkbase
101.DEF*XBRL Taxonomy Extension Definition Database
101.LAB*XBRL Taxonomy Extension Label Linkbase
101.PRE*XBRL Taxonomy Extension Presentation Linkbase
104*The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (included as Exhibit 101)
*Filed herewith
**Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act
+Indicates management contract or compensatory plan.

30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROCKWELL MEDICAL, INC.
(Registrant)
Date: November 14, 2022/s/ Mark Strobeck
Mark Strobeck, Ph.D.
Chief Executive Officer (Principal Executive Officer and Interim Financial Officer)
31
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Rockwell Medical Charts.
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Rockwell Medical Charts.